Author reply to Letter to the Editor regarding ‘Exposures to Attention Deficit Hyperactivity Disorder medications reported to the New South Wales Poisons Information Centre (2014–2023): A retrospective study’
Restricted accessLetterFirst published online May, 2026
Author reply to Letter to the Editor regarding ‘Exposures to Attention Deficit Hyperactivity Disorder medications reported to the New South Wales Poisons Information Centre (2014–2023): A retrospective study’
BradlowRCArmstrongFOgdenE (2025) Adult Attention Deficit Hyperactivity Disorder in Australia: How its current commercial model for diagnosis and treatment is encouraging misdiagnosis. Medical Journal of Australia223: 384–386.
2.
CairnsRBuckleyN (2023) Semaglutide exposures reported to the NSW Poisons Information Centre: Effects of social media marketing and supply chain disruptions. Internal Medicine Journal53: 654–655.
3.
CairnsRAllafSBuckleyNA (2025) Cannabis poisonings in Australia following the legalisation of medicinal cannabis, 2014–24: Analysis of NSW Poisons Information Centre data. Medical Journal of Australia222: 155–157.
4.
ThomsonACairnsRFJMagotraH, et al. (2025) Exposures to attention deficient hyperactivity disorder medications reported to the New South Wales Poisons Information Centre (2014–2023): A retrospective study. Australian & New Zealand Journal of Psychiatry. Epub ahead of print 10 November. DOI: 10.1177/00048674251384053.
